GlaxoSmithKline poaches Pfizer vax leader Dormitzer after hemorrhaging vaccine R&D talent

GlaxoSmithKline has seen a host of vaccine research staffers exit the Big Pharma over the past year, but it’s hoping a big name can get its vaccine business back on track.

That name is Phil Dormitzer, M.D., Ph.D., who joins the British company as its new global head of vaccine R&D and was previously vice president and chief scientific officer for RNA and viral vaccines at rival Pfizer.